Paxlovid nirmatrelvir and ritonavir Updated Oct 30
Paxlovid is Pfizer's drug, not Enanta's. Enanta's patent litigation against Pfizer over Paxlovid has now been fully resolved against Enanta on both sides of the Atlantic: the US Federal Circuit invalidated the '953 patent in June 2026 (en banc denied September 2026), and the UPC invalidated the European EP 265 patent on October 29, 2026. With no further appeal options disclosed, the litigation catalyst is dead. Enanta's stock now trades entirely on its RSV pipeline (zelicapavir Phase 2b/3 RESOLVE trial, topline 2027; EDP-323 Phase 2a) and its AbbVie royalty revenue stream. The next hard catalyst is Q4 2026 earnings on November 16, 2026.
- Enanta has $211.5M in cash (June 30, 2026) with runway into 2029, providing financial stability to advance its RSV pipeline without near-term dilution.
- Zelicapavir (RSV N-protein inhibitor) showed positive Phase 2b data in high-risk adults (Sept 2025) and has Fast Track designation from the FDA; the registrational RESOLVE trial began dosing October 26, 2026.
- EDP-323 (RSV L-protein inhibitor) demonstrated 'unprecedented antiviral activity' in a Phase 2a human challenge study, with statistically significant viral load and symptom reductions.
- Enanta's US and European Paxlovid-related patents have both been ruled invalid (Federal Circuit June 2026, UPC October 2026), eliminating any potential royalty or damages stream from Pfizer's Paxlovid sales.
- Enanta has no approved products of its own; its only revenue ($14.36M in Q3 2026) comes from AbbVie HCV royalty payments that are declining.
- The RSV pipeline is still early-stage: zelicapavir's registrational Phase 2b/3 trial (RESOLVE) only began dosing in late October 2026, with topline data not expected until 2027, leaving a long binary-free period.